Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

3 Months Ended

Mar. 31, 2022

Note 10 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31,		December 31,
	2022		2021
Accrued clinical and development expenditure	$	18,841	$	13,436
Accrued employee expenses		5,961		11,758
Other accrued expenditure		5,945		4,388
Other		880		327
	$	31,627	$	29,909